COPENHAGEN, Denmark, April 21, 2022 — SNIPR BIOME ApS has started SNIPR001’s first dosing of the first human subjects in its phase 1 clinical trial. SNIPR001 is an orally administered CRISPR-based therapeutic.
The purpose of the study is to investigate safety and tolerability of SNIPR001 in healthy volunteers and
